Ken Griffin Alnylam Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 153,600 shares of ALNY stock, worth $37.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

153,600

Previous 255,300 39.84%

Holding current value

$37.7 Million

Previous $62 Million 31.89%

% of portfolio

0.01%

Previous 0.01%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$233.81 - $287.01 $80.3 Million - $98.5 Million	-343,357 Reduced 93.48%	23,932 $6.58 Million
Q2 2024 Aug 14, 2024	BUY	$143.31 - $247.0 $46.9 Million - $80.8 Million	327,305 Added 818.59%	367,289 $89.3 Million
Q1 2024 May 15, 2024	SELL	$146.51 - $198.2 $3.91 Million - $5.29 Million	-26,665 Reduced 40.01%	39,984 $5.98 Million
Q4 2023 Feb 14, 2024	BUY	$151.41 - $196.57 $10.1 Million - $13.1 Million	66,649 New	66,649 $12.8 Million
Q2 2023 Aug 14, 2023	SELL	$185.01 - $212.05 $13.8 Million - $15.9 Million	-74,773 Reduced 71.67%	29,563 $5.62 Million
Q1 2023 May 15, 2023	BUY	$182.66 - $235.53 $18.8 Million - $24.2 Million	102,896 Added 7145.56%	104,336 $20.9 Million
Q4 2022 Feb 14, 2023	SELL	$185.53 - $241.31 $15.1 Million - $19.6 Million	-81,132 Reduced 98.26%	1,440 $342,000
Q3 2022 Nov 14, 2022	BUY	$138.54 - $232.0 $10.4 Million - $17.4 Million	74,878 Added 973.2%	82,572 $16.5 Million
Q2 2022 Aug 15, 2022	BUY	$120.42 - $169.29 $672,666 - $945,653	5,586 Added 264.99%	7,694 $1.12 Million
Q1 2022 May 16, 2022	SELL	$127.18 - $173.91 $8.73 Million - $11.9 Million	-68,660 Reduced 97.02%	2,108 $344,000
Q4 2021 Feb 14, 2022	BUY	$159.56 - $209.29 $7.96 Million - $10.4 Million	49,889 Added 238.94%	70,768 $12 Million
Q3 2021 Nov 15, 2021	SELL	$169.75 - $207.73 $3.07 Million - $3.75 Million	-18,070 Reduced 46.39%	20,879 $3.94 Million
Q2 2021 Aug 16, 2021	SELL	$128.63 - $176.89 $10.8 Million - $14.9 Million	-84,277 Reduced 68.39%	38,949 $6.6 Million
Q1 2021 May 17, 2021	BUY	$126.83 - $175.69 $5.36 Million - $7.43 Million	42,265 Added 52.2%	123,226 $17.4 Million
Q4 2020 Feb 16, 2021	BUY	$122.97 - $147.0 $6.69 Million - $8 Million	54,428 Added 205.13%	80,961 $10.5 Million
Q3 2020 Nov 16, 2020	SELL	$121.19 - $165.49 $5.72 Million - $7.81 Million	-47,167 Reduced 64.0%	26,533 $3.86 Million
Q2 2020 Aug 14, 2020	SELL	$104.21 - $156.44 $3.82 Million - $5.73 Million	-36,658 Reduced 33.22%	73,700 $10.9 Million
Q1 2020 May 15, 2020	BUY	$93.12 - $133.99 $2.75 Million - $3.96 Million	29,585 Added 36.63%	110,358 $12 Million
Q4 2019 Feb 14, 2020	BUY	$74.51 - $124.23 $27,345 - $45,592	367 Added 0.46%	80,773 $9.3 Million
Q3 2019 Nov 14, 2019	SELL	$70.9 - $87.82 $62.8 Million - $77.8 Million	-885,638 Reduced 91.68%	80,406 $6.47 Million
Q2 2019 Aug 14, 2019	BUY	$65.86 - $92.79 $62.8 Million - $88.5 Million	953,740 Added 7751.46%	966,044 $70.1 Million
Q1 2019 May 15, 2019	SELL	$72.76 - $93.45 $1.26 Million - $1.62 Million	-17,316 Reduced 58.46%	12,304 $0
Q4 2018 Feb 14, 2019	SELL	$62.67 - $88.33 $366,995 - $517,260	-5,856 Reduced 16.51%	29,620 $2.16 Million
Q3 2018 Nov 13, 2018	SELL	$87.52 - $122.67 $106,074 - $148,676	-1,212 Reduced 3.3%	35,476 $0
Q2 2018 Aug 10, 2018	SELL	$88.31 - $107.8 $1.84 Million - $2.24 Million	-20,819 Reduced 36.2%	36,688 $0
Q4 2017 Feb 09, 2018	BUY	$114.49 - $139.98 $1.41 Million - $1.72 Million	12,286 Added 27.17%	57,507 $7.31 Million
Q3 2017 Nov 09, 2017	BUY	$72.53 - $118.27 $3.28 Million - $5.35 Million	45,221	45,221 $5.31 Million

Others Institutions Holding ALNY

# of Institutions

643

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $30.2B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account